← All trials
NCT06772168
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2024
- Primary completion
- Nov 4, 2025
- Completion date
- Aug 1, 2026
- First posted
- Jan 13, 2025
- Last posted
- Jul 28, 2025
- Enrollment
- 240
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CMG Pharmaceutical Co. LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.